Drug Profile
Research programme: spleen tyrosine kinase modulators - AbbVie
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class
- Mechanism of Action Syk kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in USA
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 21 Oct 2011 Preclinical trials in Immunological disorders in USA (unspecified route)